Small D - Search Results

1

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

Levis M, Tse KF, Smith BD, Garrett E, Small D. Levis M, et al. Among authors: small d. Blood. 2001 Aug 1;98(3):885-7. doi: 10.1182/blood.v98.3.885. Blood. 2001. PMID: 11468194 Free article.

2

Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation.

Tse KF, Mukherjee G, Small D. Tse KF, et al. Among authors: small d. Leukemia. 2000 Oct;14(10):1766-76. doi: 10.1038/sj.leu.2401905. Leukemia. 2000. PMID: 11021752

3

Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor.

Tse KF, Novelli E, Civin CI, Bohmer FD, Small D. Tse KF, et al. Among authors: small d. Leukemia. 2001 Jul;15(7):1001-10. doi: 10.1038/sj.leu.2402199. Leukemia. 2001. PMID: 11455967

4

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Tse KF, et al. Among authors: small d. Leukemia. 2002 Oct;16(10):2027-36. doi: 10.1038/sj.leu.2402674. Leukemia. 2002. PMID: 12357354

5

FLT3: ITDoes matter in leukemia.

Levis M, Small D. Levis M, et al. Among authors: small d. Leukemia. 2003 Sep;17(9):1738-52. doi: 10.1038/sj.leu.2403099. Leukemia. 2003. PMID: 12970773 Review.

6

Further activation of FLT3 mutants by FLT3 ligand.

Zheng R, Bailey E, Nguyen B, Yang X, Piloto O, Levis M, Small D. Zheng R, et al. Among authors: small d. Oncogene. 2011 Sep 22;30(38):4004-14. doi: 10.1038/onc.2011.110. Epub 2011 Apr 25. Oncogene. 2011. PMID: 21516120 Free PMC article.

7

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.

Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, Small D. Williams AB, et al. Among authors: small d. Leukemia. 2013 Jan;27(1):48-55. doi: 10.1038/leu.2012.191. Epub 2012 Jul 13. Leukemia. 2013. PMID: 22858906 Free PMC article.

8

Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.

Teller S, Krämer D, Böhmer SA, Tse KF, Small D, Mahboobi S, Wallrapp C, Beckers T, Kratz-Albers K, Schwäble J, Serve H, Böhmer FD. Teller S, et al. Among authors: small d. Leukemia. 2002 Aug;16(8):1528-34. doi: 10.1038/sj.leu.2402630. Leukemia. 2002. PMID: 12145694

9

Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.

Brown P, Levis M, McIntyre E, Griesemer M, Small D. Brown P, et al. Among authors: small d. Leukemia. 2006 Aug;20(8):1368-76. doi: 10.1038/sj.leu.2404277. Epub 2006 Jun 8. Leukemia. 2006. PMID: 16761017

10

Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.

Baldwin BR, Li L, Tse KF, Small S, Collector M, Whartenby KA, Sharkis SJ, Racke F, Huso D, Small D. Baldwin BR, et al. Among authors: small s, small d. Leukemia. 2007 Apr;21(4):764-71. doi: 10.1038/sj.leu.2404532. Epub 2007 Feb 1. Leukemia. 2007. PMID: 17268528

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,315 results

Search Page

Filters